# Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

> **NCT01754259** · PHASE3 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 47 (actual)

## Conditions studied

- Diabetes, Type I
- Diabetes, Type II
- Angina
- Coronary Artery Disease

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01754259
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01754259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01754259, "Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01754259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*